Novavax Reports Strong Q4 Earnings and Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy NVAX?
Source: NASDAQ.COM
Novavax Inc's stock surged by 17.10% as it reached a 52-week high, reflecting strong investor interest amid broader market declines.
The company reported Q4 earnings that exceeded expectations, with an EPS of $0.11 and revenue of $147.14 million, surpassing forecasts by $57.28 million. This strong performance is attributed to significant sales growth of its Nuvaxovid vaccine and effective cost management strategies. Additionally, Novavax's partnership with Pfizer, which includes a $30 million upfront payment and potential milestones of up to $500 million, further enhances its market position.
The positive earnings report and strategic partnerships have bolstered investor confidence, suggesting that Novavax is well-positioned for future growth despite the current market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVAX
Wall Street analysts forecast NVAX stock price to rise
6 Analyst Rating
3 Buy
0 Hold
3 Sell
Hold
Current: 8.640
Low
6.00
Averages
10.50
High
18.00
Current: 8.640
Low
6.00
Averages
10.50
High
18.00
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novavax Stock Rises 6% as Activist Investor Shah Capital Plans to Oppose Company's Executive Pay and Board Candidates
Stock Performance: Novavax shares have increased by 6%.
Investor Actions: Activist investors, specifically Shah Capital, plan to vote against the company's executive compensation and board nominees.
See More
Activist Investor Pressures Novavax Board Ahead of Annual Meeting
- Investor Pressure: Activist investor Shah Capital is renewing its campaign against Novavax, planning to vote against the company's board nominees and executive compensation at the upcoming annual meeting, indicating dissatisfaction with corporate governance.
- Stock Price Surge: Following the report, Novavax's shares rose 5% in premarket trading, reflecting a positive market reaction to the investor's actions and potential changes in management.
- Cost Reduction Demands: Shah Capital, which owns approximately 9% of Novavax shares, is urging the company to implement deep cost-cutting measures and to repurchase between 10 million and 20 million shares to improve financial health.
- Management Restructuring Proposal: Shah Capital also recommends reducing Novavax's senior management team by 30% and cutting board membership from eight to five, aiming to attract a strategic long-term investor to guide the company's future direction.
See More
Shah Capital Increases Stake in Novavax and Demands Management Changes
- Stake Increase: Shah Capital has increased its stake in Novavax from 9% to 9.11%, becoming the second-largest shareholder, indicating a strong interest in influencing the company's strategic direction.
- Management Change Demands: Shah Capital is pushing for a 30% reduction in the senior management team and a decrease in board members from eight to five, aiming to enhance operational efficiency and decision-making capabilities.
- Strategic Investor Call: The firm has called for a long-term strategic investor to acquire a 10% to 20% stake, intending to reshape Novavax's strategic focus, particularly in the lucrative COVID-19 and influenza combo vaccine market.
- Market Reaction: Despite bearish sentiment among retail investors, Novavax's shares surged over 6% in premarket trading following Shah Capital's announcement, reflecting market optimism regarding potential changes.
See More
SHAH CAPITAL CALLS ON NOVAVAX TO REDEEM $225 MILLION CONVERTIBLE BOND AND/OR INITIATE A BUYBACK OF 10-20 MILLION SHARES
- Financial Strategy: Novavax is considering retiring a $225 million convertible bond and may also buy back 10-20 million shares.
- Market Impact: These financial maneuvers could significantly affect Novavax's stock performance and overall market position.
See More
Novavax and Datadog Options Trading Volume Surges
- Novavax Options Volume: Novavax (NVAX) options have seen a trading volume of 22,383 contracts today, equating to approximately 2.2 million shares, which represents 53.6% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Contracts: The $8.50 strike call option for NVAX has particularly high activity, with 14,183 contracts traded today, representing about 1.4 million underlying shares, suggesting bullish sentiment among investors at this price level, potentially indicating optimism about the company's growth prospects.
- Datadog Options Activity: Concurrently, Datadog (DDOG) has recorded an options trading volume of 22,499 contracts today, also around 2.2 million shares, which is 52.7% of its average daily trading volume over the past month, reflecting ongoing investor interest in its market performance.
- Key Contract Insights: For DDOG, the $75 strike put option has seen a trading volume of 9,240 contracts, approximately 924,000 underlying shares, indicating a defensive outlook among investors at this price point, which may suggest concerns about future market volatility.
See More
Investors Should Exercise Caution with Low-Priced Stocks
- Yelp Sales Growth Weakness: Yelp (NYSE:YELP) has shown a lackluster annual growth rate of only 7.1% over the past three years, which is below the average for consumer internet companies, and projected flat sales for the next 12 months indicate a slowdown in demand that could undermine investor confidence.
- FNF Profitability Challenges: Fidelity National Financial (NYSE:FNF) has experienced a 1.6% annual contraction in net premiums over the last five years, and despite revenue growth, its earnings per share have declined by 1.3% annually, highlighting profitability pressures that may affect shareholder returns.
- Novavax Demand Plummeting: Novavax (NASDAQ:NVAX) has only achieved a 6.9% annual revenue growth over the past two years, with projected sales expected to plummet by 66.2% in the next 12 months, indicating a significant drop in vaccine demand that could lead to cash flow issues.
- Low-Priced Stock Risk Warning: While these stocks priced under $50 may seem affordable, their underlying business models and profitability are fraught with uncertainty, necessitating careful risk assessment by investors to avoid potential losses.
See More
Novavax Stock Rises 6% as Activist Investor Shah Capital Plans to Oppose Company's Executive Pay and Board Candidates
Stock Performance: Novavax shares have increased by 6%.
Investor Actions: Activist investors, specifically Shah Capital, plan to vote against the company's executive compensation and board nominees.
See More
Activist Investor Pressures Novavax Board Ahead of Annual Meeting
- Investor Pressure: Activist investor Shah Capital is renewing its campaign against Novavax, planning to vote against the company's board nominees and executive compensation at the upcoming annual meeting, indicating dissatisfaction with corporate governance.
- Stock Price Surge: Following the report, Novavax's shares rose 5% in premarket trading, reflecting a positive market reaction to the investor's actions and potential changes in management.
- Cost Reduction Demands: Shah Capital, which owns approximately 9% of Novavax shares, is urging the company to implement deep cost-cutting measures and to repurchase between 10 million and 20 million shares to improve financial health.
- Management Restructuring Proposal: Shah Capital also recommends reducing Novavax's senior management team by 30% and cutting board membership from eight to five, aiming to attract a strategic long-term investor to guide the company's future direction.
See More
Shah Capital Increases Stake in Novavax and Demands Management Changes
- Stake Increase: Shah Capital has increased its stake in Novavax from 9% to 9.11%, becoming the second-largest shareholder, indicating a strong interest in influencing the company's strategic direction.
- Management Change Demands: Shah Capital is pushing for a 30% reduction in the senior management team and a decrease in board members from eight to five, aiming to enhance operational efficiency and decision-making capabilities.
- Strategic Investor Call: The firm has called for a long-term strategic investor to acquire a 10% to 20% stake, intending to reshape Novavax's strategic focus, particularly in the lucrative COVID-19 and influenza combo vaccine market.
- Market Reaction: Despite bearish sentiment among retail investors, Novavax's shares surged over 6% in premarket trading following Shah Capital's announcement, reflecting market optimism regarding potential changes.
See More
SHAH CAPITAL CALLS ON NOVAVAX TO REDEEM $225 MILLION CONVERTIBLE BOND AND/OR INITIATE A BUYBACK OF 10-20 MILLION SHARES
- Financial Strategy: Novavax is considering retiring a $225 million convertible bond and may also buy back 10-20 million shares.
- Market Impact: These financial maneuvers could significantly affect Novavax's stock performance and overall market position.
See More
Novavax and Datadog Options Trading Volume Surges
- Novavax Options Volume: Novavax (NVAX) options have seen a trading volume of 22,383 contracts today, equating to approximately 2.2 million shares, which represents 53.6% of its average daily trading volume over the past month, indicating heightened market interest in its future performance.
- High Volume Contracts: The $8.50 strike call option for NVAX has particularly high activity, with 14,183 contracts traded today, representing about 1.4 million underlying shares, suggesting bullish sentiment among investors at this price level, potentially indicating optimism about the company's growth prospects.
- Datadog Options Activity: Concurrently, Datadog (DDOG) has recorded an options trading volume of 22,499 contracts today, also around 2.2 million shares, which is 52.7% of its average daily trading volume over the past month, reflecting ongoing investor interest in its market performance.
- Key Contract Insights: For DDOG, the $75 strike put option has seen a trading volume of 9,240 contracts, approximately 924,000 underlying shares, indicating a defensive outlook among investors at this price point, which may suggest concerns about future market volatility.
See More
Investors Should Exercise Caution with Low-Priced Stocks
- Yelp Sales Growth Weakness: Yelp (NYSE:YELP) has shown a lackluster annual growth rate of only 7.1% over the past three years, which is below the average for consumer internet companies, and projected flat sales for the next 12 months indicate a slowdown in demand that could undermine investor confidence.
- FNF Profitability Challenges: Fidelity National Financial (NYSE:FNF) has experienced a 1.6% annual contraction in net premiums over the last five years, and despite revenue growth, its earnings per share have declined by 1.3% annually, highlighting profitability pressures that may affect shareholder returns.
- Novavax Demand Plummeting: Novavax (NASDAQ:NVAX) has only achieved a 6.9% annual revenue growth over the past two years, with projected sales expected to plummet by 66.2% in the next 12 months, indicating a significant drop in vaccine demand that could lead to cash flow issues.
- Low-Priced Stock Risk Warning: While these stocks priced under $50 may seem affordable, their underlying business models and profitability are fraught with uncertainty, necessitating careful risk assessment by investors to avoid potential losses.
See More
